This HTML5 document contains 31 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Subject Item

n2:w

rdf:type

bibo:Article rdac:C10001

dcterms:isPartOf

n9:w

dcterms:subject

n4:wholeblood n4:hepatitisc n4:interferontherapy n4:monokine

dcterms:title

Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon

rdaw:P10072

n13:print n13:web

vivo:relatedBy

n8:6 n8:7 n8:3 n8:4 n8:5 n8:1 n8:2

marcrel:aut

n2:nishiojikenichi n2:sakamotoshinichi n2:kashimakei n2:sakamotomasafumi n2:yasuikohichiroh n2:okanouetakeshi n2:itohyoshito

dcterms:abstract

Abstract. Using our scoring system, we studied the production of monokines (interleukin-1α, interleukin-1β, tumor necrosis factor-α, and interleukin-6) by lipopolysaccharide-stimulated peripheral whole blood in 35 patients with chronic hepatitis C during the interferon-α/β therapy. It decreased in 25.7% (9/35, group A), fluctuated in 60.0% (21/35, group B), and increased in 14.3% (5/35, group C). The patients in group A were younger than those in group B (P<0.05). The histological grade of injury was milder in group A than in group B or C. The rate of sustained response was 66.7% (6/9) in group A, 19.0% (4/21) in group B, and 40.0% (2/5) in group C (P=0.0184, group A versus group B). In summary, monokine production by peripheral whole blood varied during interferon therapy for chronic hepatitis C patients. No significant change was noted in 60% of the patients. However, patients with decreased monokine production were younger, with a mild histological grade, and likely to respond to the interferon therapy.

hub:articleType

n11:liverinfectiousinflammatoryandmetabolicdisorders n15:originalpaper

hub:publisher-id

BF02063248

dcterms:dateCopyrighted

1995

dcterms:rightsHolder

n5:plenumpublishingcorporation

hub:isPartOfThisJournal

n14:w